CD274 and lung carcinoma: The independent predictive value of this signature was validated in a prospective series of 37 NSCLC treated with nivolumab, independently from PDL1 expression by IHC [15], and more recently in patients treated with pembrolizumab, in a pan-cancer clinical trial performed across 20 tumor types, including lung cancer [16].